Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 10163Triple Negative Breast Neoplasms 1042Neoplasms 572Ovarian Neoplasms 560Neoplasm Metastasis 513Colorectal Neoplasms 467Carcinoma, Non-Small-Cell Lung 465Prostatic Neoplasms 439Lung Neoplasms 432Pancreatic Neoplasms 312Melanoma 299Stomach Neoplasms 294Breast Neoplasms, Male 257Motor Activity 252Colonic Neoplasms 238Uterine Cervical Neoplasms 225Endometrial Neoplasms 221Head and Neck Neoplasms 217Carcinoma, Intraductal, Noninfiltrating 217Carcinoma, Renal Cell 191Squamous Cell Carcinoma of Head and Neck 179Sarcoma 175Urinary Bladder Neoplasms 159Brain Neoplasms 155Esophageal Neoplasms 154Breast Carcinoma In Situ 154Lymphedema 148Fatigue 136Carcinoma, Ovarian Epithelial 134Small Cell Lung Carcinoma 128

Interventions

130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × TNBC × Breast × Clear all
NCT07491822 2026-03-24

A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase NA Not yet recruiting
43 enrolled
Breast

TNBC

NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

NCT05918133 2025-03-11

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Biotheus Inc.

Phase 1/2 Active not recruiting
42 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡